

Form PTO-1390		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER P20854
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/787916
INTERNATIONAL APPLICATION NO. PCT/JP99/05378	INTERNATIONAL FILING DATE 30 September 1999	PRIORITY DATE CLAIMED 2 October 1998	
TITLE OF INVENTION METHOD FOR INDUCING CELLULAR IMMUNITY AND CELLS HAVING INDUCED CELLULAR IMMUNITY			
APPLICANT(S) FOR DO/EO/US Hiroshi SHIKU and Junzo SUNAMOTO			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.			
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.			
2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.			
3. <input checked="" type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).			
4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).			
5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))			
a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).			
b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.			
c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).			
6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).			
7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))			
a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).			
b. <input type="checkbox"/> have been communicated by the International Bureau.			
c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.			
d. <input type="checkbox"/> have not been made and will not be made.			
8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3))			
9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).			
"Unexecuted"			
10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (U.S.C. 371(c)(5)).			
Items 11 to 16 below concern other document(s) or information included:			
11. Assignee: <u>MITSUBISHI CHEMICAL CORPORATION of Tokyo, JAPAN</u>			
12. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
13. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
14. <input checked="" type="checkbox"/> A FIRST preliminary amendment.			
<input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.			
15. <input type="checkbox"/> A substitute specification.			
16. <input type="checkbox"/> A change of power of attorney and/or address letter.			
17. <input checked="" type="checkbox"/> Figure of Drawing to be published <u>1</u>			
18. <input checked="" type="checkbox"/> Other items or information:			
Cover Sheet and International Application as published in Japanese.			
PCT/RO/101-PCT Request(in Japanese).			
PCT/IB/301.			
PCT/IB/304.			
PCT/IB/308.			
PCT/IB/332.			
PCT/IB/338.			
PCT/IPEA/408(in Japanese).			
PCT/IPEA/409.			
Cover Letter under 35 USC 371 and 1.495.			
Claim of Priority.			
Sequence Listing (1 sheet)			

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/787916

INTERNATIONAL APPLICATION NO.

PCT/JP99/05378

ATTORNEY'S DOCKET NUMBER

P20854

19. The following fees are submitted:

CALCULATIONS

PTO USE ONLY

Basic National Fee (37 CFR 1.492(a)(1)-(5)):

Search report has been prepared by the EPO or JPO. \$ 860.00

International preliminary examination fee paid to USPTO (37 CFR 1.482). \$ 690.00

No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO(37 CFR 1.445(a)(2)). \$ 710.00

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO. \$1,000.00

International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4). \$ 100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

Claims	Number Filed	Number Extra	RATE		
Total Claims	14 - 20 =	0	X \$18.00	\$0.00	
Independent Claims	3 - 3 =	0	X \$80.00	\$0.00	
Multiple dependent claim(s) (if applicable)			+ \$270.00	\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$860.00	

Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.

\$

SUBTOTAL =

\$860.00

Processing fee of \$130.00 for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(f)).

+

Extension of Time fee in the amount of \$

TOTAL NATIONAL FEE =

\$860.00

Fee for recording the enclosed assignment (37 CFR 1.21(h). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property

+

TOTAL FEES ENCLOSED =

\$860.00

Amount to be refunded

\$

Charged

\$

a. ☒ A check in the amount of \$860.00 to cover the above fees is enclosed.b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0089.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO CUSTOMER NO. 7055

AT THE PRESENT ADDRESS OF:

Bruce H. Bernstein
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Bruce H. Bernstein
 SIGNATURE
 Bruce H. Bernstein
 NAME

29,027

REGISTRATION NUMBER

09/787916

532 Re PCT/PTO 30 MAR 2001

P20854.P02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant :H. SHIKU et al.

Serial No :Not Yet Assigned
(U.S. National Phase of PCT/JP99/05378)

Filed :September 30, 1999

For :METHOD FOR INDUCING CELLULAR IMMUNITY AND CELLS HAVING
INDUCED CELLULAR IMMUNITY

**COVER LETTER ACCOMPANYING U.S. NATIONAL STAGE PATENT
APPLICATION FILED UNDER 35 U.S.C. 371
AND 37 C.F.R. 1.495**

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

Enclosed is a new National Stage patent application for filing in the U.S. Patent and Trademark Office under 35 U.S.C. 371 and 37 C.F.R. 1.495. The Declaration and Power of Attorney attached thereto are in unexecuted form. A properly executed Declaration and Power of Attorney will be filed within the period of time set in a Notification to be mailed by the United States Patent and Trademark Office.

Related to this, a correspondence address is provided in
the unexecuted Declaration and Power of Attorney, and is as follows:


GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, Va. 20191

09/787916

532 R PCT/PTO 30 MAR 2001

If there any questions pertaining to this National Stage Application, the please contact the undersigned below.

Respectfully submitted,
H. SHIKU et al.


Bruce H. Bernstein Reg No
Reg. No. 29,027 33,329

March 30, 2001
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191